Bao Pharma buys back 115,200 H-shares for HKD 1.99 million, trimming free float by 0.08%

Bulletin Express07-24

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a share repurchase on 24 July 2026, acquiring 115,200 H-shares on the Hong Kong Stock Exchange.

The shares were repurchased within a price range of HKD 17.08 to HKD 17.77 apiece, translating into a total consideration of HKD 1.99 million and an average cost of HKD 17.311 per share.

Following the transaction, Bao Pharma’s issued share capital (excluding treasury shares) fell by 0.08% to 152.73 million shares, while treasury shares increased to 1.60 million. The company’s overall issued share count remained unchanged at 154.33 million.

The purchase forms part of the repurchase mandate approved on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Including the latest transaction, Bao Pharma has repurchased 1.60 million shares under this mandate, equivalent to 1.04% of the shares outstanding on the mandate’s approval date.

In line with Hong Kong listing requirements, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 23 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123845060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123845060","market":"us","top_or_hot":-1,"title":"Bao Pharma buys back 115,200 H-shares for HKD 1.99 million, trimming free float by 0.08%","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a share repurchase on 24 July 2026, acquiring 115,200 H-shares on the Hong Kong Stock Exchange.</p>\n<p>The shares were repurchased within a price range of HKD 17.08 to HKD 17.77 apiece, translating into a total consideration of HKD 1.99 million and an average cost of HKD 17.311 per share.</p>\n<p>Following the transaction, Bao Pharma’s issued share capital (excluding treasury shares) fell by 0.08% to 152.73 million shares, while treasury shares increased to 1.60 million. The company’s overall issued share count remained unchanged at 154.33 million.</p>\n<p>The purchase forms part of the repurchase mandate approved on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Including the latest transaction, Bao Pharma has repurchased 1.60 million shares under this mandate, equivalent to 1.04% of the shares outstanding on the mandate’s approval date.</p>\n<p>In line with Hong Kong listing requirements, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 23 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma buys back 115,200 H-shares for HKD 1.99 million, trimming free float by 0.08%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma buys back 115,200 H-shares for HKD 1.99 million, trimming free float by 0.08%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-24 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a share repurchase on 24 July 2026, acquiring 115,200 H-shares on the Hong Kong Stock Exchange.</p>\n<p>The shares were repurchased within a price range of HKD 17.08 to HKD 17.77 apiece, translating into a total consideration of HKD 1.99 million and an average cost of HKD 17.311 per share.</p>\n<p>Following the transaction, Bao Pharma’s issued share capital (excluding treasury shares) fell by 0.08% to 152.73 million shares, while treasury shares increased to 1.60 million. The company’s overall issued share count remained unchanged at 154.33 million.</p>\n<p>The purchase forms part of the repurchase mandate approved on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Including the latest transaction, Bao Pharma has repurchased 1.60 million shares under this mandate, equivalent to 1.04% of the shares outstanding on the mandate’s approval date.</p>\n<p>In line with Hong Kong listing requirements, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 23 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1123845060","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123845060","pubTimestamp":1784887588,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a share repurchase on 24 July 2026, acquiring 115,200 H-shares on the Hong Kong Stock Exchange. The shares were repurchased within a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝医药以199万港元回购11.52万股H股，自由流通量削减0.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a share repurchase on 24 July 2026, acquiring 115,200 H-shares on the Hong Kong Stock Exchange.\nThe shares were repurchased within a price range of HKD 17.08 to HKD 17.77 apiece, translating into a total consideration of HKD 1.99 million and an average cost of HKD 17.311 per share.\nFollowing the transaction, Bao Pharma’s issued share capital (excluding treasury shares) fell by 0.08% to 152.73 million shares, while treasury shares increased to 1.60 million. The company’s overall issued share count remained unchanged at 154.33 million.\nThe purchase forms part of the repurchase mandate approved on 26 May 2026, which authorises the company to buy back up to 15.43 million shares. Including the latest transaction, Bao Pharma has repurchased 1.60 million shares under this mandate, equivalent to 1.04% of the shares outstanding on the mandate’s approval date.\nIn line with Hong Kong listing requirements, the company is now subject to a moratorium on issuing new shares or disposing of treasury shares until 23 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123845060","isCrawlerRequest":true}